^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    rilvegostomig (AZD2936)

    i
    Other names: AZD2936, AZD-2936, AZD 2936
    Company:
    AstraZeneca, Compugen, Xoma
    Drug class:
    PD1 inhibitor, TIGIT inhibitor
    Related drugs:
    6d
    D702KC00001: A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR) (2024-519786-22-01)
    P1/2, N=43, Not yet recruiting, AstraZeneca AB
    New P1/2 trial
    |
    Cyramza (ramucirumab) • rilvegostomig (AZD2936)
    9d
    AB02: A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) (clinicaltrials.gov)
    P3, N=186, Recruiting, AstraZeneca | N=89 --> 186
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • rilvegostomig (AZD2936)
    13d
    D702NC00001: A trial to learn how safe the combination of rilvegostomig and chemotherapy is and how well it works compared to durvalumab and chemotherapy in adults with advanced biliary tract cancer (2025-523085-24-00)
    P2/3, N=89, Not yet recruiting, AstraZeneca AB
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • rilvegostomig (AZD2936)
    14d
    ARTEMIDE-01: A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P1/2, N=212, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    rilvegostomig (AZD2936)
    19d
    Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) (clinicaltrials.gov)
    P2, N=454, Recruiting, AstraZeneca | Trial completion date: Aug 2026 --> Oct 2027 | Trial primary completion date: Aug 2026 --> Oct 2027
    Trial completion date • Trial primary completion date • Pan tumor
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • 5-fluorouracil • capecitabine • prednisone • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    20d
    GEMINI-Gastric: Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=163, Recruiting, AstraZeneca | N=240 --> 163 | Trial completion date: Sep 2027 --> May 2029 | Trial primary completion date: Jul 2026 --> Nov 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CLDN18 (Claudin 18)
    |
    5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    21d
    ARTEMIDE-subQ: A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (clinicaltrials.gov)
    P1, N=40, Recruiting, AstraZeneca
    Trial initiation date
    |
    rilvegostomig (AZD2936)
    22d
    TROPION-Lung10: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (clinicaltrials.gov)
    P3, N=675, Recruiting, AstraZeneca | Trial completion date: May 2030 --> Dec 2029 | Trial primary completion date: Apr 2028 --> Dec 2029
    Trial completion date • Trial primary completion date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • ALK rearrangement • ROS1 rearrangement
    |
    Keytruda (pembrolizumab) • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936)
    1m
    ARTEMIDE-Bil01: Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (clinicaltrials.gov)
    P3, N=757, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cisplatin • gemcitabine • capecitabine • Teysuno (gimeracil/oteracil/tegafur) • rilvegostomig (AZD2936)
    1m
    ARTEMIDE-subQ: A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (clinicaltrials.gov)
    P1, N=40, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    rilvegostomig (AZD2936)
    1m
    MERIDIAN: Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC (clinicaltrials.gov)
    P2, N=102, Recruiting, University Health Network, Toronto | N=200 --> 102 | Trial completion date: Jul 2026 --> Jul 2028 | Trial primary completion date: Jul 2026 --> Sep 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    rilvegostomig (AZD2936)
    1m
    Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 (clinicaltrials.gov)
    P3, N=2130, Recruiting, AstraZeneca
    New P3 trial
    |
    PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    PD-L1 expression • CLDN18.2 expression • PD-L1 negative • CLDN18.2 positive • CLDN1 positive
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Vyloy (zolbetuximab-clzb) • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936)